External Beam Partial Breast Irradiation Most Cost-effective Treatment

June 4, 2009

External beam partial breast irradiation (EB-PBI) is the most cost-effective method for treating postmenopausal women with early-stage breast cancer based on utilities, recurrence risks and costs when compared to whole breast radiotherapy (WBRT) and brachytherapy partial breast irradiation (brachy-PBI), according to a study in the June 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
Read the rest of this entry »

Advertisements

Incyte Provides Update On Special Protocol Assessment For INCB18424 As A New Treatment For Myelofibrosis

June 1, 2009

Incyte Corporation (Nasdaq:INCY) announced that based on recent input from the U.S. Food and Drug Administration (FDA) regarding Incyte’s request for a Special Protocol Assessment (SPA) for INCB18424 for patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), it is clear that the most appropriate single primary endpoint for Incyte’s U.S. Phase III trial is the proportion of treated patients achieving a 35% reduction in spleen volume as compared to patients receiving placebo.
Read the rest of this entry »


Fear Of Family Reaction Is Barrier To Treatment For Depressed Teens

May 27, 2009

Although teen depression poses a widespread problem for which proven treatments exist, few depressed teens receive any care.

Why don’t they undergo treatment? The answer depends whether you ask parents or the adolescents themselves, according to a study in the June issue of the journal Medical Care.

“With teenagers, treatment decisions greatly involve other parties, especially parents. For instance, teenagers often rely on adults for transportation. Doctors need a sense not just of what the teen thinks or what the parent thinks, but what both think,” said Lisa Meredith, Ph.D., lead author of the new study.
Read the rest of this entry »


FDA Approves Samsca For The Treatment Of Hyponatremia

May 24, 2009

The FDA (Food and Drug Administration) has approved Samsca (tolvaptan), in tablet form, for the treatment of hyponatremia. Hyponatremia is when levels of sodium in the blood are abnormally low – it is associated with dehydration.

Norman Stockbridge, M.D., Director, Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, FDA, said “With the approval of Samsca, physicians will have an additional tool to treat hyponatremia.”
Read the rest of this entry »


Cook Medical Brings Advanced Endovascular Thoracic Aneurysm Treatment To Canadians

May 23, 2009

In a move reflecting the rapid acceptance of Cook Medical’s advanced endogaft for thoracic aortic aneurysm worldwide, the company has received approval to market the Zenith TX2 TAA Endovascular Graft in Canada. Globally, the Zenith TX2 Endovascular Graft is now available in more than 60 markets, including the United States, Canada, the United Kingdom, European Union, Australia and others internationally.

“Physicians around the world have made Cook’s Zenith AAA Endograft the world’s best-selling device of its kind, and we’re now seeing similar momentum in the growing market for endovascular treatment of thoracic aortic aneurysms,” said Phil Nowell, global leader of Cook’s aortic intervention business unit.
Read the rest of this entry »


Yale Team Identifies Key To Potential New Treatment For Allergy-Induced Asthma

May 22, 2009

In research that could lead to new asthma drugs, scientists at Yale School of Medicine, Hydra Biosciences of Cambridge, Massachusetts, and the University of California, San Francisco have discovered that a protein may be a trigger of allergy-induced asthma in mice. They also demonstrated how a drug known to reduce inflammatory and neuropathic pain may also inhibit asthma symptoms in mice. Their paper is published in the May 18-22 online Early Edition of the Proceedings of the National Academy of Sciences.
Read the rest of this entry »


Inventors Develop Novel Technique To Help Customize, Enhance The Effectiveness Of Bladder Cancer Treatment

May 18, 2009

Researchers in the University of Virginia Department of Urology have developed a novel method that could help physicians determine the best course of treatment for patients suffering from bladder cancer.

Bladder cancer is typically treated by neoadjuvant chemotherapy, a treatment in which chemotherapy is administered to reduce the size of the cancer prior to surgery, with the two most commonly used chemotherapeutic regimens being M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and GemCis (gemcitabine and cisplatin). While M-VAC has long been considered the more potent regimen and is often offered as the gold standard for treatment, it is quite toxic and known to successfully treat only about 25 percent of patients who receive it. Recent studies in metastatic cancer suggest that GemCis is equally potent and may be better tolerated among patients; thus, it is commonly used in the neoadjuvant setting.
Read the rest of this entry »